

## Income statement

### Three months ended 31st December 2009

	Results before major restructuring £m	Major restructuring £m	Total £m	Results before major restructuring \$m	Major restructuring \$m	Total \$m
<b>TURNOVER</b>	<b>8,094</b>	-	<b>8,094</b>	<b>13,032</b>	-	<b>13,032</b>
Cost of sales	(2,098)	(21)	(2,119)	(3,373)	(38)	(3,411)
Gross profit	5,996	(21)	5,975	9,659	(38)	9,621
Selling, general and administration	(2,780)	(174)	(2,954)	(4,465)	(276)	(4,741)
Research and development	(1,092)	(35)	(1,127)	(1,761)	(56)	(1,817)
Other operating income	553	-	553	875	-	875
<b>OPERATING PROFIT</b>	<b>2,677</b>	<b>(230)</b>	<b>2,447</b>	<b>4,308</b>	<b>(370)</b>	<b>3,938</b>
Finance income	5	-	5	9	-	9
Finance expense	(213)	-	(213)	(343)	-	(343)
Profit on disposal of interest in associate	-	-	-	2	-	2
Share of after tax profits of associates and joint ventures	11	-	11	18	-	18
<b>PROFIT BEFORE TAXATION</b>	<b>2,480</b>	<b>(230)</b>	<b>2,250</b>	<b>3,994</b>	<b>(370)</b>	<b>3,624</b>
Taxation	(646)	64	(582)	(1,044)	103	(941)
<b>PROFIT AFTER TAXATION FOR THE PERIOD</b>	<b>1,834</b>	<b>(166)</b>	<b>1,668</b>	<b>2,950</b>	<b>(267)</b>	<b>2,683</b>
Profit attributable to minority interests	38	-	38	61	-	61
Profit attributable to shareholders	1,796	(166)	1,630	2,889	(267)	2,622
	1,834	(166)	1,668	2,950	(267)	2,683
<b>EARNINGS PER SHARE</b>	<b>35.4p</b>		<b>32.1p</b>	<b>57.3¢</b>		<b>52.0¢</b>
Diluted earnings per share	35.1p		31.8p	56.9¢		51.5¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

## Income statement

### Twelve months ended 31st December 2009

	Results before major restructuring £m	Major restructuring £m	Total £m	Results before major restructuring \$m	Major restructuring \$m	Total \$m
<b>TURNOVER</b>	<b>28,368</b>	-	<b>28,368</b>	<b>44,254</b>	-	<b>44,254</b>
Cost of sales	(7,095)	(285)	(7,380)	(11,068)	(445)	(11,513)
Gross profit	21,273	(285)	20,988	33,186	(445)	32,741
Selling, general and administration	(9,200)	(392)	(9,592)	(14,352)	(612)	(14,964)
Research and development	(3,951)	(155)	(4,106)	(6,164)	(241)	(6,405)
Other operating income	1,135	-	1,135	1,771	-	1,771
	<b>9,257</b>	<b>(832)</b>	<b>8,425</b>	<b>14,441</b>	<b>(1,298)</b>	<b>13,143</b>
<b>OPERATING PROFIT</b>						
Finance income	70	-	70	109	-	109
Finance expense	(780)	(3)	(783)	(1,216)	(5)	(1,221)
Profit on disposal of interest in associate	115	-	115	179	-	179
Share of after tax profits of associates and joint ventures	64	-	64	100	-	100
	<b>8,726</b>	<b>(835)</b>	<b>7,891</b>	<b>13,613</b>	<b>(1,303)</b>	<b>12,310</b>
<b>PROFIT BEFORE TAXATION</b>						
Taxation	(2,443)	221	(2,222)	(3,811)	345	(3,466)
	<b>6,283</b>	<b>(614)</b>	<b>5,669</b>	<b>9,802</b>	<b>(958)</b>	<b>8,844</b>
<b>PROFIT AFTER TAXATION FOR THE PERIOD</b>						
Profit attributable to minority interests	138	-	138	215	-	215
Profit attributable to shareholders	6,145	(614)	5,531	9,587	(958)	8,629
	<b>6,283</b>	<b>(614)</b>	<b>5,669</b>	<b>9,802</b>	<b>(958)</b>	<b>8,844</b>
<b>EARNINGS PER SHARE</b>	<b>121.2p</b>		<b>109.1p</b>	<b>189.1¢</b>		<b>170.2¢</b>
Diluted earnings per share	120.3p		108.2p	187.7¢		168.8¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

## Turnover

### Pharmaceuticals

Three months ended 31st December 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
<b>Respiratory</b>	<b>1,914</b>	<b>910</b>	<b>594</b>	<b>410</b>	<b>3,087</b>	<b>1,468</b>	<b>958</b>	<b>661</b>
<i>Avamys/Veramyst</i>	33	15	11	7	53	24	18	11
<i>Flixonase/Flonase</i>	35	6	10	19	58	10	16	32
<i>Flixotide/Flovent</i>	222	115	49	58	357	185	79	93
<i>Seretide/Advair</i>	1,366	704	436	226	2,203	1,135	704	364
<i>Serevent</i>	61	20	29	12	98	32	47	19
<i>Ventolin</i>	139	48	42	49	223	77	68	78
<i>Zyrtec</i>	22	-	-	22	35	-	-	35
<b>Anti-virals</b>	<b>1,033</b>	<b>413</b>	<b>251</b>	<b>369</b>	<b>1,674</b>	<b>674</b>	<b>408</b>	<b>592</b>
<b>HIV</b>	412	189	155	68	667	305	252	110
<i>Agenerase, Lexiva</i>	44	25	14	5	72	40	23	9
<i>Combivir</i>	109	47	37	25	176	76	59	41
<i>Epivir</i>	30	12	11	7	49	20	18	11
<i>Epzicom/Kivexa</i>	149	63	63	23	241	102	102	37
<i>Trizivir</i>	49	26	19	4	79	42	31	6
<i>Ziagen</i>	27	13	9	5	44	21	15	8
<i>Valtrex</i>	222	129	41	52	368	217	67	84
<i>Relenza</i>	256	62	39	155	408	97	65	246
<i>Zeffix</i>	55	4	7	44	90	7	11	72
<b>Central nervous system</b>	<b>504</b>	<b>178</b>	<b>146</b>	<b>180</b>	<b>814</b>	<b>288</b>	<b>236</b>	<b>290</b>
<i>Imigran/Imitrex</i>	81	43	25	13	130	69	41	20
<i>Lamictal</i>	132	72	39	21	213	117	63	33
<i>Requip</i>	65	16	37	12	104	26	59	19
<i>Requip XL</i>	40	12	27	1	64	19	44	1
<i>Seroxat/Paxil</i>	139	10	22	107	225	17	35	173
<i>Treximet</i>	14	14	-	-	23	23	-	-
<i>Wellbutrin/Wellbutrin XL</i>	22	10	9	3	37	17	15	5
<b>Cardiovascular and urogenital</b>	<b>615</b>	<b>375</b>	<b>155</b>	<b>85</b>	<b>993</b>	<b>605</b>	<b>251</b>	<b>137</b>
<i>Arixtra</i>	74	43	26	5	119	69	42	8
<i>Avodart</i>	143	83	39	21	231	135	63	33
<i>Coreg, Coreg CR</i>	31	31	-	-	51	52	-	(1)
<i>Fraxiparine</i>	60	-	45	15	97	-	73	24
<i>Levitra</i>	17	16	1	-	28	26	2	-
<i>Lovaza</i>	129	128	-	1	208	207	-	1
<i>Vesicare</i>	29	29	-	-	46	46	-	-
<i>Volibris</i>	7	-	7	-	12	-	12	-
<b>Metabolic</b>	<b>300</b>	<b>150</b>	<b>69</b>	<b>81</b>	<b>486</b>	<b>243</b>	<b>112</b>	<b>131</b>
<i>Avandia products</i>	191	109	40	42	310	177	65	68
<i>Avandia</i>	112	69	15	28	182	111	25	46
<i>Avandamet</i>	69	33	24	12	112	53	40	19
<i>Bonviva/Boniva</i>	67	41	23	3	108	66	37	5
<b>Anti-bacterials</b>	<b>409</b>	<b>41</b>	<b>181</b>	<b>187</b>	<b>662</b>	<b>67</b>	<b>292</b>	<b>303</b>
<i>Augmentin</i>	173	9	82	82	279	14	132	133
<b>Oncology and emesis</b>	<b>170</b>	<b>86</b>	<b>52</b>	<b>32</b>	<b>274</b>	<b>138</b>	<b>84</b>	<b>52</b>
<i>Hycamtin</i>	45	26	15	4	72	42	24	6
<i>Promacta</i>	5	5	-	-	8	8	-	-
<i>Tyverb/Tykerb</i>	48	14	21	13	78	22	34	22
<i>Zofran</i>	24	(1)	12	13	39	(1)	19	21
<b>Vaccines</b>	<b>1,523</b>	<b>294</b>	<b>794</b>	<b>435</b>	<b>2,419</b>	<b>469</b>	<b>1,258</b>	<b>692</b>
<i>Boostrix</i>	35	17	11	7	57	28	17	12
<i>Cervarix</i>	38	4	19	15	63	6	33	24
<i>Fluarix, FluLaval</i>	42	5	11	26	69	9	19	41
<i>Flu Pre-Pandemic</i>	836	162	511	163	1,306	254	797	255
<i>Hepatitis</i>	151	51	64	36	245	84	103	58
<i>Infanrix, Pediarix</i>	153	27	101	25	248	44	163	41
<i>Rotarix</i>	70	17	14	39	114	27	23	64
<i>Synflorix</i>	48	-	11	37	75	-	17	58
<b>Other</b>	<b>311</b>	<b>3</b>	<b>119</b>	<b>189</b>	<b>500</b>	<b>4</b>	<b>191</b>	<b>305</b>
	<b>6,779</b>	<b>2,450</b>	<b>2,361</b>	<b>1,968</b>	<b>10,909</b>	<b>3,956</b>	<b>3,790</b>	<b>3,163</b>
Stiefel products	137				211			
	<b>6,916</b>				<b>11,120</b>			

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

## Turnover

### Pharmaceuticals

Twelve months ended 31st December 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
<b>Respiratory</b>	<b>6,977</b>	<b>3,323</b>	<b>2,201</b>	<b>1,453</b>	<b>10,884</b>	<b>5,184</b>	<b>3,433</b>	<b>2,267</b>
<i>Avamys/Veramyst</i>	142	68	45	29	221	106	70	45
<i>Flixonase/Flonase</i>	171	27	43	101	267	42	67	158
<i>Flixotide/Flovent</i>	775	396	178	201	1,209	618	278	313
<i>Seretide/Advair</i>	4,977	2,592	1,609	776	7,764	4,043	2,510	1,211
<i>Serevent</i>	236	73	116	47	368	114	181	73
<i>Ventolin</i>	477	153	150	174	744	239	234	271
<i>Zyrtec</i>	75	-	-	75	117	-	-	117
<b>Anti-virals</b>	<b>4,150</b>	<b>1,897</b>	<b>1,074</b>	<b>1,179</b>	<b>6,474</b>	<b>2,959</b>	<b>1,676</b>	<b>1,839</b>
<b>HIV</b>	<b>1,605</b>	<b>716</b>	<b>635</b>	<b>254</b>	<b>2,504</b>	<b>1,117</b>	<b>991</b>	<b>396</b>
<i>Agenerase, Lexiva</i>	178	99	62	17	278	154	97	27
<i>Combivir</i>	425	187	151	87	663	292	235	136
<i>Epivir</i>	129	48	49	32	201	75	76	50
<i>Epzicom/Kivexa</i>	546	223	244	79	852	348	381	123
<i>Trizivir</i>	201	104	82	15	313	162	128	23
<i>Ziagen</i>	105	51	35	19	164	79	55	30
<i>Valtrex</i>	1,294	942	160	192	2,019	1,469	250	300
<i>Relenza</i>	720	137	212	371	1,123	213	331	579
<i>Zeffix</i>	217	17	29	171	339	27	45	267
<b>Central nervous system</b>	<b>1,870</b>	<b>651</b>	<b>574</b>	<b>645</b>	<b>2,917</b>	<b>1,016</b>	<b>895</b>	<b>1,006</b>
<i>Imigran/Imitrex</i>	266	123	96	47	415	192	150	73
<i>Lamictal</i>	500	267	154	79	780	417	240	123
<i>Requip</i>	209	26	138	45	326	41	215	70
<i>Requip XL</i>	123	32	89	2	192	50	139	3
<i>Seroxat/Paxil</i>	523	42	99	382	816	66	154	596
<i>Treximet</i>	55	55	-	-	86	86	-	-
<i>Wellbutrin/Wellbutrin XL</i>	132	88	30	14	206	137	47	22
<b>Cardiovascular and urogenital</b>	<b>2,298</b>	<b>1,415</b>	<b>583</b>	<b>300</b>	<b>3,585</b>	<b>2,207</b>	<b>910</b>	<b>468</b>
<i>Arixtra</i>	254	141	95	18	396	220	148	28
<i>Avodart</i>	530	319	148	63	827	498	231	98
<i>Coreg, Coreg CR</i>	172	171	-	1	268	267	-	1
<i>Fraxiparine</i>	229	-	173	56	357	-	270	87
<i>Levitra</i>	75	70	4	1	117	109	6	2
<i>Lovaza</i>	450	448	-	2	702	699	-	3
<i>Vesicare</i>	104	104	-	-	162	162	-	-
<i>Volibris</i>	19	-	18	1	30	-	28	2
<b>Metabolic</b>	<b>1,181</b>	<b>581</b>	<b>275</b>	<b>325</b>	<b>1,843</b>	<b>907</b>	<b>429</b>	<b>507</b>
<i>Avandia products</i>	771	425	171	175	1,203	663	267	273
<i>Avandia</i>	462	276	67	119	721	430	105	186
<i>Avandamet</i>	268	122	99	47	418	190	155	73
<i>Bonviva/Boniva</i>	255	155	89	11	398	242	139	17
<b>Anti-bacterials</b>	<b>1,592</b>	<b>173</b>	<b>662</b>	<b>757</b>	<b>2,484</b>	<b>270</b>	<b>1,033</b>	<b>1,181</b>
<i>Augmentin</i>	667	45	295	327	1,040	70	460	510
<b>Oncology and emesis</b>	<b>629</b>	<b>308</b>	<b>204</b>	<b>117</b>	<b>981</b>	<b>480</b>	<b>318</b>	<b>183</b>
<i>Hycamtin</i>	172	100	59	13	268	156	92	20
<i>Promacta</i>	13	13	-	-	20	20	-	-
<i>Tyverb/Tykerb</i>	169	54	75	40	264	84	117	63
<i>Zofran</i>	109	9	52	48	170	14	81	75
<b>Vaccines</b>	<b>3,706</b>	<b>815</b>	<b>1,744</b>	<b>1,147</b>	<b>5,781</b>	<b>1,271</b>	<b>2,721</b>	<b>1,789</b>
<i>Bostrix</i>	139	73	40	26	217	114	62	41
<i>Cervarix</i>	187	4	138	45	292	6	216	70
<i>Fluarix, FluLaval</i>	211	73	71	67	329	114	111	104
<i>Flu Pre-Pandemic</i>	883	187	525	171	1,378	292	819	267
<i>Hepatitis</i>	665	257	262	146	1,037	401	408	228
<i>Infanrix, Pediarix</i>	649	134	406	109	1,012	209	633	170
<i>Rotarix</i>	282	76	53	153	440	118	83	239
<i>Synflorix</i>	73	-	32	41	114	-	50	64
<b>Other</b>	<b>1,063</b>	<b>17</b>	<b>364</b>	<b>682</b>	<b>1,658</b>	<b>26</b>	<b>568</b>	<b>1,064</b>
	<b>23,466</b>	<b>9,180</b>	<b>7,681</b>	<b>6,605</b>	<b>36,607</b>	<b>14,320</b>	<b>11,983</b>	<b>10,304</b>
Stiefel products	248				382			
	<b>23,714</b>				<b>36,989</b>			

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

## Turnover

### Consumer Healthcare

Three months ended 31st December 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
<b>Over-the-counter medicines</b>	<b>612</b>	<b>185</b>	<b>221</b>	<b>206</b>	<b>989</b>	<b>299</b>	<b>355</b>	<b>335</b>
<i>alli</i>	40	22	17	1	66	36	29	1
<i>Breathe Right</i>	22	11	5	6	35	18	8	9
Cold sore franchise	25	11	10	4	41	18	16	7
<i>Nicotene</i> replacement therapy	90	63	19	8	146	102	31	13
<i>Panadol</i>	104	-	33	71	168	-	52	116
<i>Tums</i>	26	23	-	3	42	37	-	5
<b>Oral healthcare</b>	<b>375</b>	<b>75</b>	<b>196</b>	<b>104</b>	<b>607</b>	<b>121</b>	<b>317</b>	<b>169</b>
<i>Aquafresh</i> franchise	121	22	72	27	196	35	117	44
<i>Biotene</i>	7	5	1	1	12	9	2	1
Dental care	87	19	33	35	141	31	53	57
<i>Sensodyne</i> franchise	114	27	50	37	185	43	81	61
<b>Nutritional healthcare</b>	<b>191</b>	<b>-</b>	<b>107</b>	<b>84</b>	<b>311</b>	<b>-</b>	<b>174</b>	<b>137</b>
<i>Horlicks</i>	55	-	6	49	90	-	10	80
<i>Lucozade</i>	86	-	74	12	140	-	120	20
<i>Ribena</i>	38	-	26	12	61	-	42	19
	<b>1,178</b>	<b>260</b>	<b>524</b>	<b>394</b>	<b>1,907</b>	<b>420</b>	<b>846</b>	<b>641</b>

## Turnover

### Consumer Healthcare

Twelve months ended 31st December 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
<b>Over-the-counter medicines</b>	<b>2,319</b>	<b>722</b>	<b>748</b>	<b>849</b>	<b>3,618</b>	<b>1,126</b>	<b>1,167</b>	<b>1,325</b>
<i>alli</i>	203	96	105	2	317	150	164	3
<i>Breathe Right</i>	92	50	22	20	143	78	34	31
Cold sore franchise	96	46	38	12	150	72	59	19
<i>Nicotene</i> replacement therapy	339	247	64	28	529	385	100	44
<i>Panadol</i>	393	-	99	294	613	-	154	459
<i>Tums</i>	106	92	1	13	165	143	2	20
<b>Oral healthcare</b>	<b>1,484</b>	<b>299</b>	<b>760</b>	<b>425</b>	<b>2,315</b>	<b>466</b>	<b>1,186</b>	<b>663</b>
<i>Aquafresh</i> franchise	496	93	291	112	774	145	454	175
<i>Biotene</i>	26	19	3	4	41	30	5	6
Dental care	336	77	125	134	524	120	195	209
<i>Sensodyne</i> franchise	457	104	195	158	713	162	304	247
<b>Nutritional healthcare</b>	<b>851</b>	<b>-</b>	<b>457</b>	<b>394</b>	<b>1,327</b>	<b>-</b>	<b>713</b>	<b>614</b>
<i>Horlicks</i>	255	-	19	236	398	-	30	368
<i>Lucozade</i>	376	-	323	53	587	-	504	83
<i>Ribena</i>	160	-	113	47	249	-	176	73
	<b>4,654</b>	<b>1,021</b>	<b>1,965</b>	<b>1,668</b>	<b>7,260</b>	<b>1,592</b>	<b>3,066</b>	<b>2,602</b>

## Balance sheet

	31st December 2009 £m	31st December 2009 \$m
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	9,374	15,092
Goodwill	3,361	5,411
Other intangible assets	8,183	13,174
Investments in associates and joint ventures	895	1,441
Other investments	454	731
Deferred tax assets	2,374	3,822
Derivative financial instruments	68	109
Other non-current assets	583	939
<b>Total non-current assets</b>	<b>25,292</b>	<b>40,719</b>
<b>Current assets</b>		
Inventories	4,064	6,543
Current tax recoverable	58	93
Trade and other receivables	6,492	10,452
Derivative financial instruments	129	208
Liquid investments	268	432
Cash and cash equivalents	6,545	10,537
Assets held for sale	14	23
<b>Total current assets</b>	<b>17,570</b>	<b>28,288</b>
<b>TOTAL ASSETS</b>	<b>42,862</b>	<b>69,007</b>
<b>LIABILITIES</b>		
<b>Current liabilities</b>		
Short-term borrowings	(1,471)	(2,368)
Trade and other payables	(6,772)	(10,904)
Derivative financial instruments	(168)	(270)
Current tax payable	(1,451)	(2,336)
Short-term provisions	(2,256)	(3,632)
<b>Total current liabilities</b>	<b>(12,118)</b>	<b>(19,510)</b>
<b>Non-current liabilities</b>		
Long-term borrowings	(14,786)	(23,805)
Deferred tax liabilities	(645)	(1,038)
Pensions and other post-employment benefits	(2,981)	(4,799)
Other provisions	(985)	(1,586)
Other non-current liabilities	(605)	(974)
<b>Total non-current liabilities</b>	<b>(20,002)</b>	<b>(32,202)</b>
<b>TOTAL LIABILITIES</b>	<b>(32,120)</b>	<b>(51,712)</b>
<b>NET ASSETS</b>	<b>10,742</b>	<b>17,295</b>
<b>EQUITY</b>		
Share capital	1,416	2,280
Share premium account	1,368	2,202
Retained earnings	6,321	10,717
Other reserves	900	1,449
<b>Shareholders' equity</b>	<b>10,005</b>	<b>16,108</b>
Minority interests	737	1,187
<b>TOTAL EQUITY</b>	<b>10,742</b>	<b>17,295</b>

US dollar amounts shown above are a convenience transaction of the sterling amounts using the period end rate of £1/\$1.61.